Oxycodone versus fentanyl for intravenous patient-controlled analgesia after laparoscopic supracervical hysterectomy

A prospective, randomized, double-blind study

Nan Seol Kim, MD, a, Jeong Seok Lee, MD, PhD b, c, Su Yeon Park, PhD c, Ae Li Ryu, MD, PhD d, Hea Rim Chun, MD, a Ho Soon Chung, MD a, Kyou Sik Kang, MD, PhD a, Jin Hun Chung, MD, PhD a, Kyung Taek Jung, MD a, Seong Taek Mun, MD, PhD d

Abstract

Background: Oxycodone, a semisynthetic thebaine derivative opioid, is widely used for the relief of moderate to severe pain. The aim of this study was to compare the efficacy and side effects of oxycodone and fentanyl in the management of postoperative pain by intravenous patient-controlled analgesia (IV-PCA) in patients who underwent laparoscopic supracervical hysterectomy (LSH).

Methods: The 127 patients were randomized to postoperative pain treatment with either oxycodone (n=64, group O) or fentanyl group (n=63, group F). Patients received 7.5 mg oxycodone or 100 μg fentanyl with 30 mg ketorolac at the end of anesthesia followed by IV-PCA (potency ratio 75:1) for 48 hours postoperatively. A blinded observer assessed postoperative pain based on the numerical rating scale (NRS), infused PCA dose, patient satisfaction, sedation level, and side effects.

Results: Accumulated IV-PCA consumption in group O was less (63.5 ± 23.9 mL) than in group F (85.3 ± 24.1 mL) during the first 48 hours postoperatively (P = 0.012). The NRS score of group O was significantly lower than that of group F at 4 and 8 hours postoperatively (P < 0.001); however, the incidence of postoperative nausea and vomiting (PONV), dizziness, and drowsiness was significantly higher in group O than in group F. Patient satisfaction was lower in group O than in group F during the 48 hours after surgery (P < 0.001).

Conclusions: Oxycodone IV-PCA (potency ratio 1:75) provided superior analgesia to fentanyl IV-PCA after LSH; however, the higher incidence of side effects, including PONV, dizziness, and drowsiness, suggests that the doses used in this study were not equipotent.

Abbreviations: ASA = American Society of Anesthesiologists, F = fentanyl, IV-PCA= intravenous patient-controlled analgesia, LSH = laparoscopic supracervical hysterectomy, MOAA/S scale = modified observer’s assessment of alertness/sedation scale, NRS= numerical rating scale, O = oxycodone, PONV = postoperative nausea and vomiting.

Keywords: Fentanyl, oxycodone, postoperative pain

1. Introduction

In response to developments in surgical and anesthetic techniques, postoperative morbidity and mortality have rapidly decreased, allowing anesthesiologists to focus on specific issues related to an operation. Eberhart et al.\(^1\) reported that postoperative nausea and vomiting (PONV), as well as pain, are major concerns of surgical patients. Accordingly, methods to relieve both have been examined in several studies.

Inadequate postoperative pain control may result in harmful physiological and psychological reactions that lead to postoperative complications. In addition, the hindered recovery may delay the resumption of normal daily activities, thus decreasing the patient’s degree of satisfaction, especially if chronic pain develops.\(^2\) Among the various methods of controlling postoperative pain, intravenous patient-controlled analgesia (IV-PCA) has been used extensively, based on its improved pain control and minimal side effects.\(^3\)

Dihydroxycodeinone (oxycodone) is a semisynthetic opioid derived from thebaine, extracted from the opium poppy; as a μ-opioid receptor agonist, it is used for the control of moderate to severe pain.\(^4\) Fentanyl is an opioid analgesic most commonly used in Korea in postoperative IV-PCA. Intravenous oxycodone was recently approved by Korea’s Ministry of Food
and Drug Safety (MFDS) for IV-PCA and released onto the market in 2013. Consequently, clinical experience regarding the efficacy of oxycodone in IV-PCA is limited.\[^{[1]}\]

In the implementation of IV-PCA, the choice of an appropriate analgesic and control of the appropriate dose and lockout interval are critical to the reduction of side effects and the achievement of effective analgesia. The administration of oxycodone at too high a dose to patients sensitive to opioids may not only cause minor side effects, such as PONV, but also respiratory depression, bradycardia, apnea, hypotension, circulatory collapse, respiratory arrest, and death.\[^{[2]}\]\[^{[3]}\] Therefore, the safe, recommended doses of fentanyl and oxycodone, the 2 opioid analgesics frequently used in IV-PCA, must be carefully determined, taking into account the direct conversion factor. Previous reports have shown that the dose conversion ratio from morphine to oxycodone and from fentanyl to morphine is 1:1.\[^{[6]}\]

In the present study, using a fentanyl–oxycodone dose conversion ratio of 1:75 on the basis of previous reports,\[^{[7,8]}\] patients who were administered IV-PCA fentanyl or oxycodone for 48 hours postoperatively.

2. Materials and methods

This study was approved by the institutional review board at Soonchunhyang University Cheonan Hospital, Korea. The 130 adult patients were between the ages of 18 and 65 years, with American Society of Anesthesiologists (ASA) physical status of 1 or 2, and had requested postoperative IV-PCA for LSH scheduled to be performed at our hospital. Patients with a history of bleeding tendency, hepatitis, or renal failure; those with habitual sedative or other drug use; those with psychiatric disease; and those who were inappropriate candidates for IV-PCA were excluded from the study.

On the day before surgery, patients were informed of the purpose of the study, the PCA method, NRS, and the possible side effects of either form of IV-PCA. All patients included in the study provided written informed consent, after which they were randomly allocated to either the fentanyl (fentanyl citrate; Guju, Seoul, Korea) group (group F, n = 65) or the oxycodone (OxyNorm; Mundipharma, Seoul, Korea) group (group O, n = 65). Group allocation was performed by a blinded observer according to a computer-generated simple randomization code.

On the morning before the operation, vascular access was secured using an 18-G needle. The patients were transported to the operation room without preanesthetic medication. Upon their arrival, they were connected to an electrocardiograph, a noninvasive blood pressure monitor, and a pulse oximeter. Anesthesia was induced by the intravenous injection of 2 mg propofol/kg, and 0.3 mg rocuronium bromide/kg (Esmeron, Organon, Netherlands). Following endotracheal intubation, oxygen and air were supplied at a fraction of inspired oxygen (FiO\(_2\)) of 0.4 together with desflurane (end-tidal concentration of 6.0–7.0 vol %), maintaining an end-tidal carbon dioxide level of 35 to 40 mmHg. To ensure an appropriate anesthetic depth, the desflurane concentration was controlled so that blood pressure and heart rate values were held within 20% of the preoperative measurements; 0.5 to 1 µg fentanyl/kg was used for analgesia as necessary. After completion of the operation, desflurane and air were discontinued. Pyridostigmine and glycopyrrolate were injected to reverse the muscle relaxation. Patients were extubated after verifying a sufficient recovery of consciousness and spontaneous respiration. The IV-PCA device (Ambix Anapa; IWha-Fresenius Kabi, Seoul, Korea) was then connected. Patients in group F were injected with a loading dose of 100 µg of fentanyl and 30 mg of ketorolac, and those in group O with 7.5 mg of oxycodone and 30 mg of ketorolac. All patients were administered 0.3 mg of ramatroban to prevent PONV, the most common side effect of IV-PCA. For group F patients, 700 µg of fentanyl, 150 µg of ketorolac, and 0.6 mg of ramatroban were mixed with saline to a total volume of 100 mL; continuous infusion was set to 14 µg/h, a bolus dose of 0.5 mL, and a lockout interval of 15 minutes. For group O, based on a fentanyl–oxycodone dose conversion ratio of 1:75, 52.5 mg of oxycodone, 150 mg of ketorolac, and 0.6 mg of ramatroban were mixed with saline to a total volume of 100 mL; continuous infusion was set to 1050 µg/h, a bolus dose of 0.5 mL, and a 15-minute lockout interval.

The intensity of pain was assessed with the NRS, in which a score of “0” corresponds to “no pain” and “100” to “worst pain imaginable.” In patients with a NRS score between 30 and 50, representing moderate pain, if the established dose of analgesics had been injected and the patient requested further pain control, an additional intravenous injection of 30 mg of ketorolac was administered. In patients with a NRS score ≥50, representing high-intensity pain, the request for further pain control was met by an additional intravenous injection of 1 µg fentanyl per kg.

The sedation level was assessed using the modified observer’s assessment of alertness/sedation (MOAA/S) scale (0, does not respond to noxious stimuli; 1, does not respond to mild prodding or shaking; 2, responds only after mild prodding or shaking; 3, responds only after name is called loudly or repeatedly; 4, lethargic response to name spoken in normal tone; 5, responds readily to name spoken in normal tone). Respiratory depression was defined as a respiratory rate of <8 breaths/min. In patients with a MOAA/S scale score ≤1, or in those with respiratory depression, PCA was immediately stopped and 0.01 mg naloxone/kg was intravenously injected. Other side effects (PONV, dizziness, pruritus, and headache) were also monitored. Patients with severe PONV received an additional intravenous injection of 10 mg of metoclopamide. Those with pruritus were intravenously injected with 25 mg of pheniramine.

Patient satisfaction, graded as very satisfied, satisfied, neutral, and dissatisfied, was measured at 8 and 48 hours postoperatively.

2.1. Statistical analysis

The effective number of patients was determined with reference to a previous study.\[^{[11]}\] The primary endpoint was thus determined as the NRS score at 30 minutes postoperatively. The clinically significant effect size was an average primary endpoint difference between the 2 groups of 7.5, with a standard deviation of 15.28. Calculation of the sample size showed that at a significance level (α) of 0.05 (1-sided) and power (1 – β) of 0.8,
Table 1

Demographic data and anesthesia characteristics of the patients.

|                      | Group F (n = 63) | Group O (n = 64) |
|----------------------|------------------|------------------|
| Age, y               | 46.3 ± 5.2       | 46.1 ± 5.4       |
| ASA physical status II| 48/15            | 45/19            |
| Smoker/nonsmoker     | 7/56             | 7/57             |
| History of motion sickness or PONV | 27 (42.0%)   | 27 (42.2%)       |
| Height, cm           | 158.1 ± 4.5      | 159.0 ± 4.6      |
| Weight, kg           | 58.7 ± 9.0       | 60.1 ± 7.9       |
| Duration of surgery, min | 78.3 ± 30.3     | 70.8 ± 22.1      |
| Duration of anesthesia, min | 105.8 ± 30.7 | 96.1 ± 24.9      |

Values are expressed as the mean±SD or number of patients (%). There were no statistically significant differences between the 2 groups. ASA = American Society of Anesthesiologists, Group F = fentanyl group, Group O = oxycodone group, PONV = postoperative nausea and vomiting.

52 patients were required for each group. With an expected dropout rate of 10%, the final estimated number of participants in each group was 65.

The statistical analysis was performed using SPSS software for Windows (version 18, SPSS Inc, Chicago, IL). Measurement data are expressed as the mean and standard deviation. Demographic data were analyzed using Pearson χ² test or Student t test. The generalized estimating equation method was used to compare IV-PCA quantity and pain level between the 2 groups postoperatively for 48 hours, both at rest and during coughing. A P value <0.001 was considered to be statistically significant. The incidence of side effects and the degree of patient satisfaction were compared in groups F and O using Pearson χ² test or Fisher exact test. A P value <0.05 was considered to be statistically significant.

3. Results

The 130 patients enrolled in the study were randomized with respect to treatment, with 65 patients allocated to each of the 2 groups. Three patients withdrew from the study: 1 patient in group O did not meet the inclusion criteria and was therefore excluded, and 1 patient each in groups O and F discontinued treatment because of PONV. Therefore, 127 patients completed the study: 64 in group F and 63 in group O.

There were no statistically significant differences between the 2 groups with respect to age, height, weight, duration of surgery or anesthesia, ASA physical status, motion sickness, or smoking history (Table 1).

The 2 groups did not significantly differ with respect to infused PCA dose at 30 minutes or 4, 8, 24, or 48 hours postoperatively; however, the amount of PCA during the first 48 hours after surgery was significantly less in group O than in group F (Fig. 1). The difference between the 2 groups in the NRS at rest was not significantly different at 0.5, 24, or 48 hours postoperatively, but at 4 and 8 hours, it was significantly lower in group O than in group F (P < 0.001) (Fig. 2). The NRS on coughing was significantly lower in group O than in group F only at 4 hours postoperatively (P < 0.001) (Fig. 3).

The nausea level at 4, 8, 24, and 48 hours, but not at 0.5 hour, was significantly higher in group O than in group F. The incidence of postoperative vomiting was significantly higher in group O only at 8 hours postoperatively (Table 2), as was the administration of additional antiemetic drugs (P < 0.05) (Table 3). In contrast, the administration of additional analgesics was significantly more frequent in group F at 8h postoperatively (Table 3) whereas, overall, dizziness and drowsiness occurred significantly more often in group O (Table 4). Respiratory depression was not observed in either of the 2 groups, nor were there significant differences in their sedation scores.

Postoperative patient satisfaction also did not significantly differ between the 2 groups at 8 hours postoperatively; however, at 48 hours, it was significantly higher in group F than in group O (Table 5).

![Figure 1](image1.png)

**Figure 1.** Accumulated fentanyl and oxycodone consumption (mL) 0.5 to 48 hours postoperatively (mean±standard deviation). *P < 0.001 for an interaction effect between group and time. The P value was calculated using the generalized estimating equation method. PCA = patient-controlled analgesia.

![Figure 2](image2.png)

**Figure 2.** NRS at rest 0.5 to 48 hours postoperatively (mean±standard deviation). The possible range is between 0 and 100 mm. *P < 0.001 for an interaction effect between group and time. The P value was calculated using the generalized estimating equation method. NRS = numeric rating scale.
4. Discussion

Generally, laparoscopic surgery offers several advantages over laparotomy, including less pain, faster recovery, and an improved cosmetic effect.[12] However, patients frequently experience moderate pain even after "minor" surgery because analgesics are used postoperatively at doses smaller than those actually required.[13] The establishment of an appropriate IV-PCA dose is important for the postoperative management also of patients undergoing minor surgery. This study compared the analgesic effect, PCA quantity, side effects, and degree of satisfaction in the use of IV-PCA in patients who underwent LSH, a relatively minor operation. Fentanyl is commonly used in IV-PCA in our hospital, whereas oxycodone is a newly released intravenous analgesic with a shorter history of use in IV-PCA. The fentanyl–oxycodone dose conversion ratio used in our study was 1:75.

The opioids widely administered for IV-PCA are full μ-receptor-binding agonists, with no analgesic ceiling in pain control. However, a clinical ceiling set to prevent side effects, such as sedation and, particularly, respiratory depression, may prevent the use of an appropriate pain control dose.[13] Ketorolac, when used in combination with opioids, has an opioid-sparing effect, enhancing the analgesic effects of opioids while reducing their side effects.[14] Therefore, we included ketorolac in the IV-PCA to reduce both the side effects of opioids and the pain caused by motion.[2,15]

Fentanyl, which is a 4-amidopiperidine compound, has extremely high lipid solubility and a rapid onset of action. Its analgesic effect occurs within 30 seconds after injection and reaches a peak in 5 minutes, reflecting its fast and extensive redistribution in the body. Thus, fentanyl has the properties of an ideal IV-PCA drug, as well as the advantage of not producing active metabolites that may cause respiratory depression.[3,7]

Oxycodone, a newly released intravenous analgesic, is a semisynthetic opioid that was developed in Germany in 1916 in an attempt to improve opioids.[4] It is structurally analogous to morphine, which is a global reference standard for opioids, and

| Table 2 | Incidence (%) of postoperative nausea and vomiting. |
|---------|-----------------------------------------------------|
| Time after surgery, h | Group F (n=63) | Group O (n=64) |
| | Nausea (%) | Vomiting (%) | Nausea (%) | Vomiting (%) |
| 0.5 | 2 (3.2) | 0 (0) | 2 (3.1) | 0 (0) |
| 4 | 8 (12.7) | 3 (4.8) | 21 (32.8) | 2 (3.1) |
| 8 | 9 (14.3) | 1 (1.6) | 21 (32.8) | 9 (14.1) |
| 24 | 9 (14.3) | 5 (7.9) | 31 (48.4) | 8 (12.5) |
| 48 | 2 (3.2) | 3 (4.8) | 18 (28.1) | 2 (3.1) |

Values are expressed as the number (%) of patients.

* P < 0.05 in a comparison of the 2 groups.

| Table 3 | Use of rescue analgesics and antiemetics. |
|---------|------------------------------------------|
| Time after surgery, h | Group F (n=63) | Group O (n=64) |
| | Analgesics (%) | Anti-emetics (%) | Analgesics (%) | Anti-emetics (%) |
| 0.5 | 23 (36.5) | 0 (0) | 10 (15.6) | 2 (3.1) |
| 4 | 15 (23.8) | 5 (7.9) | 1 (1.6) | 3 (4.7) |
| 8 | 0 (0) | 2 (3.2) | 1 (1.6) | 10 (15.6) |
| 24 | 4 (6.3) | 3 (4.8) | 3 (4.7) | 9 (14.1) |
| 48 | 1 (1.6) | 2 (3.2) | 0 (0) | 3 (4.7) |

Values are expressed as the number (%) of patients.

| Table 4 | Incidence (%) of adverse events. |
|---------|----------------------------------|
| Group F (n=63) | Group O (n=64) |
| Dizziness | 16 (25.3%) | 43 (67.1%) |
| Drowsiness | 2 (3.2%) | 16 (25.0%) |
| Headache | 9 (14.3%) | 8 (13.3%) |
| Pruritis | 3 (4.8%) | 9 (14.0%) |
| Respiratory depression | 0 (0%) | 0 (0%) |

Values are expressed as the number (%) of patients.

* P < 0.05 in a comparison of the 2 groups.

| Table 5 | Patient satisfaction at 8 and 48 hours postoperatively. |
|---------|------------------------------------------------------|
| Time after surgery (h) | Group F (n=63) | Group O (n=64) |
| 8 | Very satisfied | 11 (17.5%) | 11 (17.2%) |
| | Satisfied | 38 (60.3%) | 32 (50.0%) |
| | Neutral | 14 (22.2%) | 13 (20.3%) |
| | Dissatisfied | 0 (0%) | 8 (12.5%) |
| 48 | Very satisfied | 16 (25.4%) | 7 (10.9%) |
| | Satisfied | 38 (60.3%) | 27 (42.1%) |
| | Neutral | 7 (11.1%) | 20 (31.2%) |
| | Dissatisfied | 2 (3.2%) | 10 (15.6%) |

Values are expressed as the number (%) of patients.

* P < 0.05 in a comparison of the 2 groups.
has a 1:1 analgesic strength in postoperative pain involving somatic and visceral pain factors.\[^{10}\]\] Oxycodeone is metabolized in the liver by cytochrome P450 enzymes. However, because it acts on μ-opioid receptors, oxycodone has the typical side effects of other opioids, including nausea, constipation, drowsiness, vomiting, pruritus, and dizziness.\[^{14}\]\]

Koch et al.\[^{8}\]\] compared the effect of intravenous fentanyl and oxycodone for postoperative pain control in the recovery room during the first 2 postoperative hours in patients who underwent laparoscopic cholecystectomy. The total amount of fentanyl used was 200 μg and that of oxycodone 15 mg, consistent with a fentanyl-oxycodone dose conversion ratio of ∼1:75. Hwang et al.\[^{9}\]\] also reported a fentanyl-oxycodone dose conversion ratio of ∼1:75 during the 48 hours after laparoscopic cholecystectomy, which suggested that oxycodone is more potent than morphine. Based on these results, we anticipated that fentanyl and oxycodone would produce similar analgesic effects when used in IV-PCA at a ratio of 1:75; however, this was not the case. Although, as expected, the NRS score at 30 minute postoperatively was not significantly different between groups O and F, the use of rescue analgesics was significantly more frequent in the latter group (Table 3). Additionally, for acute postoperative pain 4 and 8 hours postoperatively, the analgesic effect of oxycodone was superior to that of fentanyl (Figs. 1 and 2), and PCA consumption at 48 hours was significantly greater in group F (85.3 ± 2.41 mL vs 63.5 ± 23.9 mL, *P* = 0.012). The difference between the results of this study and previous ones can be explained by the shorter monitoring times (2 hours postoperatively) or the absence of continuous infusion in IV-PCA administered for 48 hours. The difference in the pharmacokinetics of the 2 drugs should be taken into account when IV-PCA, including continuous infusion, is used for the continuous injection of drugs over several days, as in the present study. The analgesic onset time of oxycodone is 2 to 3 minutes, which is as short as that of fentanyl, whereas oxycodone has a slightly longer duration of action (11/2: 4 hour 52 minutes vs 3 hours 39 minutes). However, owing to redistribution, the analgesic effect of fentanyl after a single intravenous injection is much shorter than that of oxycodone.\[^{10}\]\]

Female sex, nonsmoking behavior, history of PONV, and the intraoperative or postoperative use of an opioid are high-risk factors for PONV, which is among the most common postoperative side effect. The incidence of PONV in one study was 21% with 1 risk factor, 39% with 3 risk factors, 61% with 3 risk factors, and 79% with 4 risk factors.\[^{16}\]\] Administration of a preventive antiemetic drug is recommended for patients at high risk. Because most patients in our study had at least 3 risk factors, ramosetron was included as a PONV preventive antiemetic. However, despite its administration in group O, the incidence of PONV was ≥30% beginning 4 hours postoperatively. This rate was higher than expected and higher than that of group F, which indicates that the administration of oxycodone was excessive and that the fentanyl–oxycodone dose conversion ratio of 1:75 requires adjustment.

Our survey of postoperative patient satisfaction showed that the 2 groups did not significantly differ at 8 hours postoperatively, whereas at 48 hours, patient satisfaction was significantly higher in group F than in group O (Table 5). With regard to acute postoperative pain within 8 hours postoperatively, the analgesic effect of oxycodone was superior to that of fentanyl such that patient satisfaction was not significantly different between the 2 groups, although side effects, including PONV, were frequently observed in group O. In contrast, at 48 hours postoperatively, whereas the pain score was similar between the 2 groups, patient satisfaction was lower in group O than in group F because of the high incidences of PONV, dizziness, and drowsiness in oxycodone-treated patients.

The lack of a significant difference in the sedation score between the 2 groups probably reflected the fact that the patients included in this study were healthy, ≤65 years of age, and had an ASA physical status of 1 or 2.

The present study also had several limitations. First, the continuous infusion rate, lockout interval, and bolus dose could not be controlled because an Anapa PCA pump was used during IV-PCA to investigate the analgesic quantity during the first 48 postoperative hours, which was the primary outcome. Hence, the equianalgesic dose between fentanyl and oxycodone could not be accurately calculated. Second, patient age is an important factor in the use of oxycodone, with patients older than 70 years having an average oxycodone exposure 40% to 80% higher than that of young adult patients.\[^{17}\]\] Because our study included only patients who were 65 years or younger, a further study of patients older than 70 years of age is required.

In conclusion, oxycodone, administered at a fentanyl–oxycodone dose conversion ratio of 1:75, may be an appropriate drug that can replace fentanyl in IV-PCA, based on our finding that oxycodone is much more effective than fentanyl in relieving acute postoperative pain within the first 8 hours postoperatively. However, owing to the high incidence of side effects, especially PONV, the oxycodone–fentanyl dose conversion ratio must be adjusted.

References

1. Eberhart LH, Morin AM, Wulf H, et al. Patient preferences for immediate postoperative recovery. Br J Anaesth 2002;89:760–1.
2. Joshi GP, Ogumaiske BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin North America 2005;23:21–36.
3. Grass JA. Patient-controlled analgesia. Anesth Analg 2005;101:S44–61.
4. Kalso E. Oxycodeone. J Pain Symptom Manage 2005;39:547–56.
5. Choi IM. A new therapeutic option for postoperative pain management with oxycodone HCl injection. Korean J Anesthesiol 2016;69:211–8.
6. Silvasti M, Rosenberg P, Seppala T, et al. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 1998;42:576–80.
7. Momenni M, Crucitti M, De Kock M. Patient-controlled analgesia in the management of postoperative pain. Drugs 2006;66:3231–37.
8. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672–87.
9. Hwang BY, Kwon JY, Kim E, et al. Oxycodeone vs. fentanyl patient-controlled analgesia after laparoscopic cholecystectomy. Int J Med Sci 2014;11:638–62.
10. Koch S, Allburg P, Spangsberg N, et al. Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecystectomy: a randomised double-blind study. Acta Anaesthesiol Scand 2008;52:845–50.
11. Kim NS, Kang KS, Yoo SH, et al. A comparison of oxycodone and fentanyl in intravenous patient-controlled analgesia after laparoscopic hysterectomy. Korean J Anesthesiol 2015;68:261–6.
12. Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2015;Cd003677.
[13] Gerbershagen HJ, Aduckathil S, van Wijck AJ, et al. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology 2013;118:934–44.

[14] Picard P, Bazin JE, Conio N, et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain 1997;73:401–6.

[15] Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014;118:85–113.

[16] Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91:693–700.

[17] Liukas A, Kuusniemi K, Aantaa R, et al. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging 2011;28:41–50.